ASH® 2025 Highlights: Presenter Vignette – Amir Fathi
Amir Fathi
MD
Harvard Medical School
6
Results from paradigm – a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia.
This program has been made possible through unrestricted support from Astellas, Daiichi Sankyo, Eli Lilly and Merck.
